Private Advisor Group’s Oncolytics Biotech ONCY Stock Holding History

Private Advisor Group’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,210	Closed	-$24K	–	1947
2020 Q4	$24K	Sell	10,210 -526	-5%	-$1.26K	﹤0.01%	1740
2020 Q3	$18K	Hold	10,736	–	–	﹤0.01%	1538
2020 Q2	$20K	Buy	10,736 +210	+2%	+$395	﹤0.01%	2586
2020 Q1	$15K	Buy	+10,526	New	+$26.3K	﹤0.01%	1396

Other funds holding ONCY

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Private Advisor Group's ONCY Position: Q1 2021 in Review

Private Advisor Group sold out of Oncolytics Biotech (ONCY) in Q1 2021, closing a stake of 10,210 shares — an estimated $24K sold.

Private Advisor Group first reported a position in ONCY in Q1 2020 and held it in 4 quarters. The position peaked at $24K in Q4 2020. 41 funds tracked by Wall St. Rank hold ONCY as of Q1 2021.

Private Advisor Group reported no remaining Oncolytics Biotech position as of Q1 2021 after selling out during the quarter.
Private Advisor Group sold 10,210 Oncolytics Biotech shares in Q1 2021, an estimated $24K.
Private Advisor Group first reported a position in Oncolytics Biotech in Q1 2020 and held it in 4 quarters.
Private Advisor Group's Oncolytics Biotech position peaked at $24K in Q4 2020.
41 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2021.

Based on Private Advisor Group's 13F filing for Q1 2021, filed 22 Apr 2021.